MediciNova, Inc.Company Review & Valuation

4875
Tokyo Stock Exchange
Latest Price
568.00JPY
Market Capitalization
24.90bJPY

About MediciNova, Inc.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuShow moreroprotective agent for the treatment of neurological disorders consisting of primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction. Its product pipeline also comprises MN-221 (bedoradrine), a selective -adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.Show less

Industry
Biotechnology
HQ Location
La Jolla, California

Stock Price

Price data not available for MediciNova, Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

Alexion Pharmaceuticals
NanoString Technologies
Amgen
KalVista Pharmaceuticals

back to top